Answers are grounded in this paper and cite their sources.
The designed nanodrug composite showed the best release in conditions mimicking the physiological conditions of the intestinal lumen. Given the fact that no overuse or genetic event would cause the emergence of antimicrobial resistance against the MSCs CM-CS NPs nanodrug, it could be considered as a promising alternative for the treatment of MDR V. cholerae infections in clinical settings.
No takes yet. Share an insight, caveat, or question.
Saberpour et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: